FDA reviewing Boehringer drug use for asthma treatment
The Ridgefield Press Under the new application it is being evaluated as a long-term, once-daily, add-on maintenance treatment of asthma in patients 12 years of age and older who remain symptomatic on at least inhaled corticosteroids, and it is not currently approved for … |
View full post on asthma – Google News